Literature DB >> 10403919

Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides.

H Müller1, G Mayer, B Behnke, E Heimüller, G Hamscher, D Immler, C Siethoff, H E Meyer, M Schreiber.   

Abstract

HIV-1 can be neutralized by soluble factors produced and secreted by activated CD8+ T cells. Production of such anti-viral CD8 factors (including chemokines) can be induced with IL-2 or phytohaemagglutinin (PHA). In addition to PHA or IL-2, we have co-stimulated CD8+ T cells with PHA/IL-2 and a mixture of thymic peptides (TP) of molecular weights below 10 kD. For the activation, CD8+ T cells were purified from peripheral blood mononuclear cells of HIV-1- individuals and any resultant anti-viral activity was monitored using an HIV-1 neutralization assay. Using HIV-1 isolates highly resistant to chemokine inhibition we detected significantly higher levels of HIV-1 neutralizing activity in CD8+ T cell culture supernatants which had been co-activated with TP. When the TP-induced anti-viral activity was monitored, neutralization of both non-syncytia-inducing (NSI) and syncytia-inducing (SI) patient isolates was enhanced by 38% (NSI, PHA +/- TP), 66% (SI, PHA +/- TP), 28% (NSI, IL-2 +/- TP), and 57% (SI, IL-2 +/- TP) compared with the anti-viral activity present in supernatants from CD8+ T cell cultures stimulated only with PHA or IL-2. Peptide sequence analysis of purified TP showed that the TP mixture predominantly contains peptides with homology to human histone and collagen sequences. Our data demonstrate that CD8+ T cells are additionally activated by a mixture of TP. In this way, the production of HIV-1 neutralizing CD8 factors can be enhanced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403919      PMCID: PMC1905482          DOI: 10.1046/j.1365-2249.1999.00936.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Thymopentin (TP-5) therapy during lymphadenopathy syndrome (LAS/ARC): preliminary report.

Authors:  P Costigliola; E Ricchi; V Colangeli; C Pintori; P Boni; F Chiodo
Journal:  J Exp Pathol       Date:  1987

2.  Biochemical characterization and immunomodulatory action of thymic components as determined by flow cytometry on human lymphocytes.

Authors:  C Birr; B Bohn; K H Jaeger
Journal:  Thymus       Date:  1987

3.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

4.  CD8+ T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells.

Authors:  B Røsok; P Voltersvik; B M Larsson; J Albert; J E Brinchmann; B Asjö
Journal:  AIDS Res Hum Retroviruses       Date:  1997-01-01       Impact factor: 2.205

5.  Thymopentin treatment in AIDS and pre-AIDS patients.

Authors:  N Clumeck; S Cran; P Van de Perre; F Mascart-Lemone; J Duchateau; K Bolla
Journal:  Surv Immunol Res       Date:  1985

6.  A calf thymus acid lysate improves clinical symptoms and T-cell defects in the early stages of HIV infection: second report.

Authors:  G Valesini; V Barnaba; R Benvenuto; F Balsano; P Mazzanti; P Cazzola
Journal:  Eur J Cancer Clin Oncol       Date:  1987-12

7.  A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.

Authors:  C M Walker; J A Levy
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

8.  CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Cell Immunol       Date:  1989-04-01       Impact factor: 4.868

9.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins.

Authors:  Y Riviere; F Tanneau-Salvadori; A Regnault; O Lopez; P Sansonetti; B Guy; M P Kieny; J J Fournel; L Montagnier
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

Review 10.  Enhanced immune response and antitumor immunity with combinations of biological response modifiers.

Authors:  E Garaci; A Mastino; C Favalli
Journal:  Bull N Y Acad Med       Date:  1989-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.